ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.
ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.
On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator.
Co-Founder & CEO
Senior Vice President, Research and Development
Jean Pierre Julien
Co-Founder & CSO
ImStar Therapeutics Selects Lead Drug Candidate for ALS
StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
Documentaries, videos and podcasts